Medtronic's Evolut Aortic Valve Replacement Shows Positive Outcomes Even After Two Years

Medtronic Plc MDT has announced the complete two-year outcomes from a low-risk trial comparing the Evolut transcatheter aortic valve replacement (TAVR) system to open-heart surgery in characteristically younger, healthier aortic stenosis patients.
Data were presented at the EuroPCR 2021 e-Course.
The results showed the Evolut TAVR platform was non-inferior to surgery for the primary endpoint of all-cause mortality or disabling stroke at two years (4.3% for TAVR versus 6.3% for surgery).
At two years, the study showed that improved safety shown early on for TAVR was sustained over time.
Better hemodynamic (blood flow) performance for TAVR with statistically significantly lower mean aortic valve gradient (9.0 mm Hg versus 11.7 mm Hg) was seen.
A larger effective orifice area than surgery (2.2 cm2 versus 2.0 cm2) at two years was observed.
Numerically lower rates of death in the TAVR arm (3.5% versus 4.4%), heart failure hospitalizations (5.3% versus 7.1%), and disabling stroke (1.5% versus 2.7%) compared to surgery at two years were reported.
The prosthesis-patient mismatch was lower for TAVR than surgery at two years, with a difference of 2.1% versus 4.9% in the severe category.
Valve thrombosis rates showed no signs of increase and remained low at two years.
Price Action: MDT shares are up 0.76% at $126.49 during the market session on the last check Tuesday.

Overview Rating:

Good

100

0100